Predictive Oncology (POAI) announced its Helomics division has executed on an agreement between the company and Interpace Diagnostics Group, Inc. or Interpace (IDXG), collectively known as 'the Companies", to build AI-driven models of thyroid cancer in order to enhance diagnosis of as well as therapeutic options for thyroid cancer. This phase of the agreement is expected to leverage real world clinical data from Interpace's two thyroid products, ThyGeNEXT and ThyraMIR, coupled with drug response profiles of thyroid tumors from Helomics' patient-derived tumor profiling platform to build D-CHIP AI-driven models of thyroid cancer. The models will help identify potential druggable targets for treatment of indolent and aggressive thyroid cancers. Ultimately, the companies hope to develop a full pipeline of products that work seamlessly together to both diagnose and assess risk for thyroid cancer in addition to providing appropriate therapy recommendations.
Predictive Oncology subsidiary Helomics announced a joint collaborative agreement with UPMC to study the use of artificial intelligence to improve clinical decision making for ovarian cancer patients. Helomics is a subsidiary of Predictive Oncology Inc., a company focused on applying artificial intelligence to personalized medicine and drug discovery. The collaboration will focus on using Helomics' artificial intelligence platform to analyze the genomic and drug response profiles of women with ovarian cancer to determine predictive value in terms of response/non-response to therapy. The parties believe that the collaboration will demonstrate the value of using AI-powered, evidence-based decision making, in the context of specific treatments on specific genotypes, to predict clinical outcomes for this group of patients. Work performed under the collaboration will be funded in part by UPMC Enterprises. UPMC Enterprises, the commercialization and innovation arm of UPMC, was established to generate and enable exceptional health care innovations focusing on two main areas: translational science and digital health solutions.
Interpace Diagnostics (IDXG) has executed an agreement with the Helomics division of Predictive Oncology (POAI). As part of this agreement, the companies expect to develop a pipeline of products that work seamlessly together to diagnose and assess the risk for thyroid cancer as well as provide appropriate therapeutic recommendations by leveraging Interpace's Thyroid products, ThyGeNEXT and ThyraMIR, coupled with Helomics' patient-derived tumor profiling and AI platform known as "D-CHIP." Under the plan for this phase of the agreement Helomics will build a model using Interpace's existing clinical data which can be utilized to identify druggable targets for treatment of indolent and aggressive thyroid cancers.